Schema-Root.org logo

 

  cross-referenced news and research resources about

 PhaRMA

Representing 50 biotech companies, PhRMA has twenty registered Lobbyists on staff and has contracted with dozens of lobby and Public Relations firms — including Akin, Gump, Strauss, Hauer & Feld, Barbour Griffith & Rogers, DCI Group, The Dutko Group, Edelman, and Bonner & Associates — to promote its members' interests. Total lobbying expenditures in 2009 were $26,465,520

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Sat. February 17, 2018 reload page to refresh

-
If the devil wears Prada, what do America's most destructive drug pushers wear? They wear smiles. The drug pushers we have in mind here have caused hundreds of thousands of deaths, enough fatalities to decrease overall U.S. life expectancy at birth for the last two years running. Yet no police SWAT ...

Deciphera pharmaceuticals Inc (Nasdaq: DCPH)'s kinase switch control platform has largely gone unnoticed on the Street. The nascent portfolio caught an analyst's attention this week. The Rating. B Riley analyst Madhu Kumar initiated coverage on Deciphera with a Buy rating and $43 price target.
Goldacre has spent years campaigning to force companies to report in all their clinical trials; many of the drugs on the market today were approved even though more than half of their trials never reported in, meaning that PhaRMA companies were able to cherry-pick the trials that yielded favorable results ...
Manhattan oncology data company Flatiron Health said Thursday it has agreed to be acquired by the Swiss drugmaker Roche for $1.9 billion. The landmark deal signals the growing strength of the city's health technology sector. Flatiron sells a specialized electronic health record system for oncology and ...
Hyderabad, called "bulk drug capital of India", contributes almost 20 per cent of PhaRMA exports from India and generates US$15 billion a year, according to the federal finance ministry. The city plays a major role in making India a leader in the global generic drug business and clinical research outsourcing.

PhaRMA unleashes lobbying power to fight surprising--and costly--changes to Medicare Part D ... PhaRMA only recently suffered in Congress' shutdown-averting spending deal, which put the industry on the hook for bigger discounts in the Medicare Part D coverage gap, but its advocates in Washington are ...
Today we will focus on Achaogen (AKAO), which got a slight boost after Tetraphase PhaRMA's (TTPH) drug failed to beat ertapenem in a late-stage cUTI study. AKAO shares were up more than 1% in early trading on Wednesday. Achaogen's plazomicin NDA is currently being reviewed by the FDA for the ...
Some of the pharmaceutical companies selling prescription opioids that have caused thousands of deaths are looking to profit from the antidote for overdoses, according to a VICE News analysis of drug approval records from Health Canada. One emergency room doctor in Toronto who regularly reverses ...
Astellas PhaRMA buying Universal Cells for $102M in Seattle's third biotech acquisition in a month. by Clare McGrane on February 15, 2018 at ... Astellas PhaRMA, a Japanese pharmaceutical and biotechnology company, is acquiring Seattle biotech Universal Cells. Astellas will pay up to $102.5 million for ...
The sticker shock for Horizon PhaRMA's Vimovo drug is magnified by the fact that the painkiller's two main ingredients can be purchased separately -- for just $36. Although patients typically pay just a fraction of the price for Vimovo, the dramatic price increase underlines what critics describe as a murky and ...
Today we will discuss Shire Plc (SHPG), which is continuing with its bad run. Year to date, SHPG shares have fallen nearly 14%. Of course, the sell-off this year can be attributed to the bearish sentiment in general in the market. But Shire also had a disappointing 2017 even as the NBI posted gains of more ...
Antares PhaRMA stock is also rising on this news because the newly approved device utilizes the company's QuickShot technology. Under the terms of the agreement between these two companies, Antares will assemble the final product and then sell it back to AMAG at cost plus a markup. Antares is then ...
Roche, the global pharmaceutical company from Switzerland, today announced it will scoop up Flatiron Health, a startup analyzing real-time oncology data to help cancer patients and doctors, in a $1.9 billion deal. Flatiron has also confirmed the deal to TechCrunch. Two years ago, Roche led a $175 ...
Shares of Antares PhaRMA Inc. ATRS, +18.69% and Amag pharmaceuticals AMAG, +29.14% soared in premarket trade Thursday, after Amag said the U.S. Food and Drug Administration has approved their Makena subcutaneous auto injector drug-device combination product, a ready-to-administer ...
A recent article arguing that "brands don't matter to patients" (Accenture Life sciences, "The Patient Has Spoken") draws some conclusions that are worthy of debate and challenge. While it's a compelling survey, I confess I struggle to accept as inevitable the conclusion that "product brands are not major ...
Expanding its global headquarters in Switzerland, Ferring pharmaceuticals is investing 30 million Swiss francs (roughly $32 million) in a new biotech center. In addition to manufacturing biologics (including Rekovelle, the latest of the company's many fertility treatments), the new facility will have discovery ...

High five: How these companies are leveraging data to engage A-list HCPs · Five things for PhaRMA marketers to know: Friday, February 9, 2018 · Big Predictions: Agency gurus on the future of data in the industry · PhRMA takes Let's Talk About Cost campaign to the public · Five things for PhaRMA marketers ...
Today we will focus on Akebia Therapeutics (AKBA) after the company provided an update to investors on its late-stage vadadustat studies. Vadadustat is AKBA's lead product candidate being evaluated for the treatment of anemia associated with chronic kidney disease (CKD). An inhibitor of Hypoxia ...
Sun PhaRMA's third-quarter profit slumps 75% on lower sales, U.S. tax changes. India's biggest drug maker says U.S. pricing environment `challenging'. Sun pharmaceutical Industries is grappling with falling drug prices in the U.S., where the Food and Drug Administration has expedited its approval rate for ...
Today was a consolidation day with no clear direction as investors brace for the inflation data tomorrow morning. Tetraphase pharmaceuticals (TTPH) stock tanked after-hours on the failure of a phase 3 trial in cUTI. Is there any value left in the stock? Buy or sell? market and sector outlook: Today was a ...
The Sackler family is best known for the buildings adorned with their names thanks to their acts of philanthropy, which is either motivated by a public spirit, or by the desperate need for some reputation washing as the public becomes increasingly aware that the family fortune was built on the perfection of ...
year ago, when Merck's (MRK 1) latest treatment for Alzheimer's disease came up a dud, the company saw a silver lining 2. By targeting patients with early forms of the disease, yet to show major symptoms, researchers saw a winning pathway for the drug, which looked like it was hitting its molecular targets.
NEW YORK -- Monday marked a change of culture for Purdue PhaRMA, the drug company that makes OxyContin and other opioids. The company will no longer market those drugs to doctors and is laying off half its sales force. After years of marketing testimonial videos and handing doctors pamphlets ...
The maker of OxyContin, one of the most prescribed and aggressively marketed opioid painkillers, will no longer tout the drug or any other opioids to doctors. The announcement, made Saturday, came as drugmaker Purdue PhaRMA faces lawsuits for deceptive marketing brought by cities and counties ...
'PhaRMA Vision 2020', which aims to make India a major hub for end-to- end drug discovery, is a great initiative by the government of India. Under this initiative, there are plans to set up a $640-million venture capital fund to enhance drug discovery and support pharmaceutical infrastructure. We look forward ...
1. government shutdown continues: The U.S. government shutdown enters its third day on Monday, with the Senate scheduled to vote at noon on a bill to reopen it for three weeks. However, it is still unclear whether the proposal will garner enough support from Democrats to pass. Scroll for more content.
A group of some of the largest hospital chains in the US has had it with Big PhaRMA price gouging, announcing their intention to form their own nonprofit drug manufacturing company. A coalition of several of America's largest hospital systems have announced that they will collaborate on the creation of a ...
Strong free cash flow allows Pfizer to return a significant amount of capital back to shareholders through dividends (3.66% annual yield) and share repurchases. Pfizer's stock trades at a discount based on historical multiples, a comparables analysis, and a discounted cash flow model. Pfizer's sales have ...
Chandigarh : With the pharmaceutical sector projected to witness a 12% compound annual growth rate (CAGR) between 2015 and 2020, the Punjab government also wants to ride the tide by projecting Mohali as a PhaRMA hub to attract key players. But it faces the biggest challenge from the ...
Having worked in a slate of senior positions in PhaRMA and biotech, John Hohneker is now taking the reins of Anokion as president and CEO. Most recently he was president of R&D at Forma Therapeutics, where he guided the company from discovery stage to clinical trials. In Hohneker, the Lausanne, ...
Today, we will discuss the ongoing takeover battle involving Novo Nordisk (NVO) and Belgian biotech Ablynx. On January 8th, Novo Nordisk went hostile with its takeover offer for Ablynx. The two companies had been in discussions over the previous month. However, Ablynx had not been open to a ...
Indian Country News is a weekly note from High Country News, as we continue to broaden our coverage of tribal affairs across the West. Asserting its role as the sovereign protector of its people, the Cherokee Nation filed an unprecedented lawsuit last year against some of the largest drug distributors in the ...
The state Attorney General's Office is taking on Big PhaRMA -- drug manufacturers, distributors and drugstores -- who put powerful, painkilling opioid drugs into the hands of Delawareans, according to a lawsuit filed Friday. The filing details the ways in which manufacturing companies like Purdue PhaRMA ...
NEWTOWN - The town's decision to join Southbury and 16 cities and towns in a lawsuit against pharmaceutical companies is just one response to an opioid addiction crisis that's becoming public enemy No. 1. Other Municipalities, including Danbury, are looking to sign on with a small law firm in the hope of ...
Patients are paying more out of their pockets for drugs. Photo: Jeffrey Greenberg / UIG via Getty Images. Health insurers and PhaRMAcy benefit managers are blasting a proposed federal policy that would lower what patients pay out of pocket when they pick up their prescriptions, saying it coddles the pharmaceutical industry ...
He explained that the agreement would give the opportunity to both parties to provide humanitarian services in general and particularly medical services to the needy people as Qatar Charity works in the charitable and humanitarian field and Qatar PhaRMA is a well-known pharmaceutical enterprise with ...
2017 turned out to be a pretty good year for PhaRMA and biotech stocks with the Nasdaq biotechnology index and the nyse ARCA pharmaceutical index gaining 18.7% and 11.8%, respectively. Although the industry continued to face headwinds in the form of drug pricing scrutiny, pricing pressure, ...
Having developed multispecific antibodies with F-star, Denali Therapeutics has joined forces with Takeda pharmaceuticals to commercialize Alzheimer's drugs using the technology. F-star's bispecific antibody technology has received validation in the form of two PhaRMA companies using it for the ...
Poverty, unemployment and inequality are perhaps the biggest challenges facing society today. These issues all urgently need solutions, and businesses bear a responsibility in helping to create them. One of the key ways in which businesses can do this is through Corporate Social Responsibility (CSR) ...
Puma plans to modify labeling in its European marketing application for its breast cancer candidate neratinib. Concert had a mixed day with the USPTO's PTAB rejecting its patent challenge, but the FDA granting Fast Track status to CTP-543. Today we will discuss the Ad Com's vote against Lipocine's ...
Every year, the biggest names in the PhaRMA industry head to San Francisco to the JPMorgan healthcare Conference. And almost every year, a couple of big industry deals get announced at the event. This year, the expectation of M&A was especially pronounced. That's in large part because of tax reform ...
Last week I was proud to file federal litigation against national pharmaceutical manufacturers for their role in creating the opioid crisis affecting Albany County and our nation. Joining me was Elizabeth Smith from the nationally respected law firm Motley Rice. The purpose of this action is to hold these ...
Strides Shasun and Sun PhaRMA continue to be in our long-term portfolios. We feel that in the long term, they will get rid of the problems that they have because of small allocations but we continue to stay allocated. Strides is a play on organic growth because of a lot of acquisitions recently and a couple of ...
Stocks such as Divi's Laboratories (up 1.70 per cent), GlaxoSmithKline pharmaceuticals (up 1.48 per cent), Aurobindo PhaRMA (up 1.43 per cent) and Dr. Reddy's Laboratories (up 1.08 ... Sun PhaRMA, Bharat petroleum corporation, Lupin and Tech Mahindra were among the top gainers in the Nifty50 index.
The company's partnership with Sanofi adds significant credibility to the story, as does management's prior experience at Novo Nordisk. This opportunity appears to be offering a potent mix of growing royalties from approved products and clinical catalysts in the next couple quarters. Readers who have ...
The PhaRMA and biotech industry will repatriate, thanks to the congressional approval, the president's tax bill, over $150 billion of cash," Marcus told Maria Bartiromo on "Mornings with Maria." Congress passed the tax bill in December, creating the a sweeping overhaul of the U.S. tax system--the largest in ...
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Allergan To Cut 1,000 jobs As A Generic Restasis Sets To Take Stage. News: Recently, Allergan (AGN) announced that it would cut up to 1,000 jobs to counter its ...
Leading PhaRMA, LLC, a Fairfield, NJ-based privately-owned generic pharmaceutical company that manufactures, markets, and distributes products to drug chains, wholesalers, and other channels, announced Friday that on December 28, 2017 it completed a financing transaction for $40 million of growth ...
In his prepared remarks, he argues that the "research agendas today in biotech and PhaRMA - and the problems we're trying to solve in global health - are starting to converge in exciting ways." He cited the link between efforts to harness the immune system to fight cancer and work on infectious diseases ...


 

news and opinion


 


 


 


 


schema-root.org

   lobbyists
     phrma

lobbyists:
     alston & bird
     capitoline
     phrma